Education
About Us
Working with TipRanks
Follow Us
Beyondspring (BYSI)
:BYSI
Top Page
Beyondspring
(NASDAQ:BYSI)
30Underperform
Beyondspring (BYSI) vs. S&P 500 (SPY)
Market Cap
$57.85M
Dividend YieldN/A
Average Volume (3M)12.99K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees40
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding40,316,320
10 Day Avg. Volume19,067
30 Day Avg. Volume12,988
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)35.66
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Beyondspring Business Overview & Revenue Model
Company DescriptionBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
How the Company Makes MoneyBeyondSpring generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to bring its products to market through a combination of direct commercialization, partnerships, and licensing agreements with other pharmaceutical companies. Revenue streams include milestone payments and royalties from partnerships, as well as potential sales revenue from its lead product, Plinabulin, once it receives regulatory approval and is commercialized. BeyondSpring may also receive funding through research grants and collaborations with academic and research institutions.
Beyondspring Financial Statement Overview
Summary
Beyondspring is experiencing severe financial difficulties. The income statement shows zero revenue in 2024, with negative profit margins and operational losses. The balance sheet reveals negative equity, high leverage, and financial instability. Cash flow is negative, with reliance on external financing, indicating significant operational and financial challenges.Income Statement
The company's income statement reveals several challenges. Total revenue dropped to zero in 2024 from $1.75 million in 2023, indicating a declining trend. Gross profit margin is non-existent due to zero revenue. Moreover, net profit margin is severely negative at -100% in 2024, with EBIT and EBITDA margins also in negative territory, pointing to significant operational losses. There is no revenue growth, which is concerning for future sustainability.20
Very Negative
Balance Sheet
The balance sheet shows financial instability with negative stockholders' equity of $32.9 million in 2024, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated reliably due to negative equity, suggesting high leverage and financial risk. Total assets have decreased over the years, and the equity ratio is negative, highlighting significant financial distress.15
Very Negative
Cash Flow
Cash flow analysis indicates ongoing operational challenges. Operating cash flow remains negative, though slightly improved from the previous year. The free cash flow is also negative, showing that the company is not generating sufficient cash to cover investments. Financing cash flow is positive, primarily due to new financing activities, suggesting reliance on external funding to sustain operations.30
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.88M | 0.00 | 1.75M | 1.35M | 1.35M | 180.00K | Gross Profit |
| 1.88M | 0.00 | 1.75M | 1.35M | 1.35M | 103.00K | EBIT |
| -17.05M | -8.75M | -23.11M | -37.24M | -66.24M | -64.21M | EBITDA |
| -16.77M | -8.75M | -21.54M | -34.96M | -64.49M | -63.66M | Net Income Common Stockholders |
| -15.57M | -11.12M | -21.03M | -36.28M | -68.21M | -61.06M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 392.00K | 2.92M | 8.00M | 37.27M | 72.37M | 109.54M | Total Assets |
| 0.00 | 34.31M | 24.81M | 46.22M | 81.65M | 117.04M | Total Debt |
| 0.00 | 589.00K | 4.00M | 4.96M | 3.58M | 4.31M | Net Debt |
| 392.00K | -2.33M | -3.81M | -29.43M | -38.05M | -105.22M | Total Liabilities |
| 0.00 | 48.60M | 48.27M | 49.23M | 60.73M | 30.41M | Stockholders Equity |
| -9.39M | -32.90M | -26.80M | -5.98M | 26.68M | 88.34M |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | -16.44M | -16.57M | -27.50M | -50.09M | -43.80M | Operating Cash Flow |
| 0.00 | -16.44M | -16.47M | -27.46M | -47.24M | -43.74M | Investing Cash Flow |
| 0.00 | -12.01M | -100.00K | 17.56M | -20.41M | -52.00K | Financing Cash Flow |
| 0.00 | 26.79M | 4.00K | 3.43M | 1.00K | 117.83M |
Beyondspring Technical Analysis
Negative
1.62
Price Trends
1.69
Negative
1.70
Negative
1.95
Negative
Market Momentum
-0.05
Positive
49.60
Neutral
36.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BYSI, the sentiment is Negative. The current price of 1.62 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.69, and below the 200-day MA of 1.95, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 49.60 is Neutral, neither overbought nor oversold. The STOCH value of 36.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BYSI.
Beyondspring Risk Analysis
Beyondspring disclosed 89 risk factors in its most recent earnings report. Beyondspring reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beyondspring Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $10.27B | 20.83 | 23.13% | ― | 18.49% | 176.71% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $1.01B | ― | -66.09% | ― | 32387.34% | 15.93% | |
42 Neutral | $11.01M | ― | -151.46% | ― | -95.23% | -325.89% | |
36 Underperform | $31.48M | ― | 41.08% | ― | -0.55% | 49.85% | |
30 Underperform | $57.85M | ― | 78.44% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
BYSI
Beyondspring
1.62
-1.66
-50.61%
EXEL
Exelixis
36.39
13.05
55.91%
GERN
Geron
1.48
-1.62
-52.26%
KPTI
Karyopharm Therapeutics
3.54
-17.38
-83.08%
AFMD
Affimed
0.71
-5.73
-88.98%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.